This document aims to provide concrete, pragmatic guidance for how TB modelling and related technical assistance is undertaken to support country decision-making. The target audience for this document are the participants and stakeholders in country-level TB modelling efforts, including the individu...als who build and apply models; policy-makers, technical experts and other members of the TB community; international funding and technical partners; and individuals and organizations engaged in supporting TB policy-making.
more
these guidelines are updated on 16 February 2021
Please check the new guideline here
https://medbox.org/document/who-guidelines-for-malaria#GO
This user guide is designed to provide national malaria control programmes with general information on glucose-6-phosphate dehydrogenase (G6PD) deficiency. Individuals with this condition may be at risk of adverse effects from medicines commonly used to cure Plasmodium vivax malaria, as well as from... other medicines and substances.
more
Q7: In individuals with bipolar mania, are a) antipsychotics, b) mood stabilizers (lithium carbonate, valproate, and carbamazepine) effective and safe
Q9: Antidepressant medicines in individuals with a depressive episode in bipolar disorder1Q9: In individuals presenting with a depressive episode in bipolar disorder, are antidepressant medicines effective and safe?
Q10: In individuals with psychotic disorders (including schizophrenia) and bipolar disorders are psychoeducation, family interventions and cognitive-behavioural therapy feasible and effective?
This report found that while European Schools are paying increasing attention to inclusion, children with disabilities continued to face problems. They are rejected, pressured into changing schools, or are not provided with appropriate accommodations and support to allow them to learn and thrive in ...an inclusive environment.
more
20 February 2013
Update on 2004 Background Paper (Written by Saloni Tanna)
Priority Medicines for Europe and the World "A Public Health Approach to Innovation"
Q10: For carers of people with dementia, does respite care when compared to care as usual, produce benefits/harm in the specified outcomes?
Q9: For carers of people with dementia, do interventions (psychoeducational, cognitive-behavioural therapy counseling/case management, general support, training of caregivers, multi-component interventions and miscellaneous interventions) when compared to placebo/comparator, produce benefits/harm in... the specified outcomes?
more
Q8: For people with dementia, what is the role of a medical review (including comorbid physical and mental conditions and medication use)?
Q4: For people with dementia with associated depression, do antidepressants when compared to placebo/comparator produce benefits/harm in the specified outcomes?
Q5: For people with dementia, which cognitive/psychosocial interventions (such as cognitive stimulation, cognitive rehabilitation, reality orientation, reminiscence therapy) when compared to placebo/comparator produce benefits/harm in the specified outcomes?
Q7: For people with dementia, who should be told of the diagnosis and how should the diagnosis be delivered?
Q3: For behavioural and psychological symptoms in people with dementia, do following drugs, when compared to placebo/comparator, produce benefits/harm in the specified outcomes?
The report “Dementia: a public health priority” has been jointly developed by WHO and Alzheimer's Disease International. The purpose of this report is to raise awareness of dementia as a public health priority, to articulate a public health approach and to advocate for action at international a...nd national levels.
Dementia is a syndrome that affects memory, thinking, behaviour and ability to perform everyday activities. The number of people living with dementia worldwide is currently estimated at 35.6 million. This number will double by 2030 and more than triple by 2050. Dementia is overwhelming not only for the people who have it, but also for their caregivers and families. There is lack of awareness and understanding of dementia in most countries, resulting in stigmatization, barriers to diagnosis and care, and impacting caregivers, families and societies physically, psychologically and economically.
Available Languages: Chinese, English, Japanese, Russian and Spanish
more
Q 10: In adults and children with epilepsy, which psychological interventions used as adjunctive therapies with antiepileptic drugs when compared to placebo/comparator produce benefits/harm in specified outcomes?
Q9. In adults and children with convulsive epilepsy in remission, when should treatment be discontinued?